STOCK TITAN
  1. Home
  2. News
  3. IKT

Inhibikase Therapeutics, Inc. - IKT STOCK NEWS

Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.

Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company dedicated to advancing medical treatments for Parkinson's disease and related disorders. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase focuses primarily on the development of protein kinase inhibitors to modify the course of neurodegenerative diseases.

The company's flagship product candidate, IkT-148009, is a selective inhibitor of the non-receptor Abelson Tyrosine Kinases aimed at treating Parkinson's disease both inside and outside the brain. IkT-148009 is also being explored for its potential in treating dysphagia and neurogenic constipation, conditions often associated with Parkinson's disease.

Another noteworthy product in Inhibikase's pipeline is IkT-001Pro, a prodrug of the anti-cancer agent imatinib. Currently in preclinical development, IkT-001Pro aims to minimize gastrointestinal side effects commonly seen in cancer treatments. The company is also developing IkT-01427, which targets the causative virus of progressive multifocal leukoencephalopathy, and the IkT-148x series, meant for treating dementia with Lewy bodies and multiple system atrophy.

In recent news, Inhibikase announced that it would host a conference call on March 28, 2024, to discuss its latest developments. Furthermore, the company is reviewing IkT-001Pro's potential as a disease-modifying treatment for Pulmonary Arterial Hypertension. Financially, the company reported $2.8 million in research and development expenses and $2.0 million in selling, general, and administrative expenses for the quarter ended March 31, 2024.

For more information, you can contact the company through Milton H. Werner, PhD, President & CEO, at 678-392-3419 or via email at info@inhibikase.com. Investor relations are handled by Alex Lobo at Stern Investor Relations, Inc.

News

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Rhea-AI Summary

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced outcomes from the final pre-IND meeting with the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. The FDA designated IkT-001Pro as a New Molecular Entity, allowing for exclusivity designations. The Company is preparing the IND application for Pro, a potential branded product for PAH, a deadly disease with treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
-
News

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Rhea-AI Summary
Inhibikase Therapeutics provided a shareholder update, highlighting progress on their 201 Trial for Parkinson's disease. The company is in the process of enrolling the last patient for the trial and has had positive interactions with the FDA regarding their IkT-001Pro development. They are planning Phase 3 protocols and exploring new indications for their therapies. Additionally, they are seeking grant support for biomarker research and considering IkT-001Pro for Pulmonary Arterial Hypertension. Overall, the company is focused on advancing their pipeline and bringing innovative treatments to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
-
News

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Rhea-AI Summary
Inhibikase Therapeutics, Inc. plans to discuss IkT-001Pro as a potential treatment for Pulmonary Arterial Hypertension with the FDA. The company aims to modify the course of PAH, a rare disease affecting the pulmonary microvasculature. Previous research suggests that IkT-001Pro may offer a safer and better-tolerated therapeutic option compared to existing treatments. The global PAH market size was $7.66 billion in 2023, with an estimated growth rate of 5.4% from 2024 to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Rhea-AI Summary
Inhibikase Therapeutics, Inc. reports financial results for Q4 and full year 2023, highlighting recent developments such as the completion of a pre-NDA meeting with the FDA for IkT-001Pro and active enrollment in the Phase 2 201 Trial of Risvodetinib for Parkinson's disease. The company also published Phase 1 results of Risvodetinib in the Journal of Parkinson's Disease. Financially, the company reported a net loss of $19.0 million for 2023, with R&D expenses of $13.6 million and SG&A expenses of $6.7 million. Cash, cash equivalents, and marketable securities were $13.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.09%
Tags
earnings
-
News

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announces Dr. Milton Werner's presentation on the 201 Trial evaluating risvodetinib for Parkinson's disease at the 2024 AD/PD Meeting. The trial aims to modify the course of Parkinson's disease and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
News

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) plans to pursue eleven indications for IkT-001Pro, a prodrug of imatinib mesylate, after positive outcomes from discussions with the FDA. The Company is confident in the NDA development process and aims to modify the course of Parkinson's disease and related disorders. The FDA's feedback indicates potential flexibility in dosage forms for IkT-001Pro, opening opportunities for broader applications beyond blood and stomach cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
News

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) has announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and the company plans to seek all 11 indications for which imatinib mesylate has been approved. In addition, the company continues to make progress in its evaluation of risvodetinib in the 201 Trial in Untreated Parkinson’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
none
-
News

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) published Phase 1 clinical studies demonstrating the safety and tolerability of risvodetinib, a potential disease-modifying therapy for Parkinson’s disease. The drug was well tolerated by healthy volunteers and patients with Parkinson’s disease, with no serious adverse events reported. The company is advancing its Phase 2 201 Trial, with topline results expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
clinical trial
-
News

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Rhea-AI Summary
Inhibikase Therapeutics, Inc. announced the retirement of Chief Financial Officer Joseph Frattaroli at the end of the first quarter of 2024. Garth Lees-Rolfe, the Vice-President for Finance, will be promoted to Chief Financial Officer. The company expressed gratitude to Joe for his years of service and highlighted the successful transition into a public company under his leadership. Dr. Milton Werner, President and CEO, commended Joe's contributions and expressed confidence in Garth's ability to drive the company's growth as the new CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
News

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) has experienced a 68% increase in stock price since October 9, 2023. The company has made significant progress in its neurodegenerative and cancer therapeutics programs, including advancing clinical trials for Parkinson's disease and Multiple System Atrophy. They have also developed technologies to improve drug absorption and have made significant strides in the commercialization of their therapeutics. The company is optimistic about transformative treatments in neurodegeneration and is looking forward to a successful 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none

FAQ

What is the current stock price of Inhibikase Therapeutics (IKT)?

The current stock price of Inhibikase Therapeutics (IKT) is $3.2 as of December 20, 2024.

What is the market cap of Inhibikase Therapeutics (IKT)?

The market cap of Inhibikase Therapeutics (IKT) is approximately 219.8M.

What does Inhibikase Therapeutics, Inc. specialize in?

Inhibikase Therapeutics specializes in developing protein kinase inhibitors to treat Parkinson's disease and related neurodegenerative disorders.

What is IkT-148009?

IkT-148009 is a selective inhibitor of Abelson Tyrosine Kinases, targeting the treatment of Parkinson's disease both inside and outside the brain.

What is the purpose of IkT-001Pro?

IkT-001Pro is a prodrug of the anti-cancer agent imatinib, designed to minimize gastrointestinal side effects during cancer treatment.

Where is Inhibikase Therapeutics headquartered?

Inhibikase Therapeutics is headquartered in Atlanta, Georgia.

When was Inhibikase Therapeutics founded?

The company was founded in 2008.

What other products are in Inhibikase's pipeline?

Other products include IkT-01427, which targets progressive multifocal leukoencephalopathy, and the IkT-148x series for treating dementia with Lewy bodies and multiple system atrophy.

Who is the President & CEO of Inhibikase Therapeutics?

Milton H. Werner, PhD, serves as the President and CEO.

How can I contact Inhibikase Therapeutics for more information?

You can contact them at 678-392-3419 or via email at info@inhibikase.com.

What are the latest financial figures for Inhibikase?

For the quarter ended March 31, 2024, Inhibikase reported $2.8 million in research and development expenses and $2.0 million in selling, general, and administrative expenses.

When is the next company conference call?

The next conference call is scheduled for March 28, 2024, at 8:00 a.m. ET.

Stock IKT logo
Inhibikase Therapeutics, Inc.

Nasdaq:IKT

IKT Rankings

#3777 Ranked by Market Cap
N/A Ranked by Dividends

IKT Stock Data

219.81M
52.56M
10.46%
11.62%
0.29%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ATLANTA